CAV regimen
WikiDoc Resources for CAV regimen |
Articles |
---|
Most recent articles on CAV regimen Most cited articles on CAV regimen |
Media |
Powerpoint slides on CAV regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on CAV regimen at Clinical Trials.gov Clinical Trials on CAV regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on CAV regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on CAV regimen Discussion groups on CAV regimen Patient Handouts on CAV regimen Directions to Hospitals Treating CAV regimen Risk calculators and risk factors for CAV regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for CAV regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:CAV Regimen; Cytoxan-Adriamycin-Vincristine Regimen; VAC Regimen
Overview
CAV regimen refers to a regimen consisting of cyclophosphamide, doxorubicin and vincristine used for the treatment of extensive-stage small cell lung cancer.[1][2]
Regimen
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Kawahara M, Tsuruta M, Furuse K, Arai R, Kodama N, Yamamoto M; et al. (1988). "[Cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of small cell lung cancer]". Gan To Kagaku Ryoho. 15 (3): 457–62. PMID 2831819.